Literature DB >> 9187463

Serum CA 125 levels and survival in advanced ovarian cancer.

K Münstedt1, M Krisch, S Sachsse, H Vahrson.   

Abstract

We made a retrospective analysis of 85 patients with elevated serum CA 125 after surgery for ovarian cancer. Absolute CA 125 serum levels were a poor guide to prognosis. However, the ratio between the serum CA 125 after the first, second, or third course of treatment and the postoperative value was an excellent guide to prognosis. These were also independent and stable in the Cox Regression analysis.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9187463     DOI： 10.1007/BF02505319

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.344


  6 in total

1.  Dynamic Optimal Strategy for Monitoring Disease Recurrence.

Authors:  Hong Li; Constantine Gatsonis
Journal:  Sci China Math       Date:  2012-08-01       Impact factor: 1.331

2.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

3.  Determination of cancer antigen 125 in ovarian carcinoma.

Authors:  V Thakur; A K Anand; U Mukherjee; D Ghosh
Journal:  Indian J Clin Biochem       Date:  2003-07

4.  Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Mi-Ok Lyu; Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

Review 5.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

6.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.